Druggable targets and therapeutic development for COVID-19
Coronavirus disease (COVID-19), which is caused by SARS-CoV-2, is the biggest challenge to the global public health and economy in recent years. Until now, only limited therapeutic regimens have been available for COVID-19 patients, sparking unprecedented efforts to study coronavirus biology. The ge...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-10-01
|
| Series: | Frontiers in Chemistry |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fchem.2022.963701/full |
| _version_ | 1828341327875538944 |
|---|---|
| author | Xiaohua Duan Lauretta A. Lacko Shuibing Chen |
| author_facet | Xiaohua Duan Lauretta A. Lacko Shuibing Chen |
| author_sort | Xiaohua Duan |
| collection | DOAJ |
| description | Coronavirus disease (COVID-19), which is caused by SARS-CoV-2, is the biggest challenge to the global public health and economy in recent years. Until now, only limited therapeutic regimens have been available for COVID-19 patients, sparking unprecedented efforts to study coronavirus biology. The genome of SARS-CoV-2 encodes 16 non-structural, four structural, and nine accessory proteins, which mediate the viral life cycle, including viral entry, RNA replication and transcription, virion assembly and release. These processes depend on the interactions between viral polypeptides and host proteins, both of which could be potential therapeutic targets for COVID-19. Here, we will discuss the potential medicinal value of essential proteins of SARS-CoV-2 and key host factors. We summarize the most updated therapeutic interventions for COVID-19 patients, including those approved clinically or in clinical trials. |
| first_indexed | 2024-04-13T23:11:13Z |
| format | Article |
| id | doaj.art-d4530190037b4b19a7d4a3e0d3df02fc |
| institution | Directory Open Access Journal |
| issn | 2296-2646 |
| language | English |
| last_indexed | 2024-04-13T23:11:13Z |
| publishDate | 2022-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Chemistry |
| spelling | doaj.art-d4530190037b4b19a7d4a3e0d3df02fc2022-12-22T02:25:33ZengFrontiers Media S.A.Frontiers in Chemistry2296-26462022-10-011010.3389/fchem.2022.963701963701Druggable targets and therapeutic development for COVID-19Xiaohua DuanLauretta A. LackoShuibing ChenCoronavirus disease (COVID-19), which is caused by SARS-CoV-2, is the biggest challenge to the global public health and economy in recent years. Until now, only limited therapeutic regimens have been available for COVID-19 patients, sparking unprecedented efforts to study coronavirus biology. The genome of SARS-CoV-2 encodes 16 non-structural, four structural, and nine accessory proteins, which mediate the viral life cycle, including viral entry, RNA replication and transcription, virion assembly and release. These processes depend on the interactions between viral polypeptides and host proteins, both of which could be potential therapeutic targets for COVID-19. Here, we will discuss the potential medicinal value of essential proteins of SARS-CoV-2 and key host factors. We summarize the most updated therapeutic interventions for COVID-19 patients, including those approved clinically or in clinical trials.https://www.frontiersin.org/articles/10.3389/fchem.2022.963701/fullSARS-CoV-2main proteasepapain-like proteaseRNA-dependent RNA polymeraseneutralizing antibodieshost factors |
| spellingShingle | Xiaohua Duan Lauretta A. Lacko Shuibing Chen Druggable targets and therapeutic development for COVID-19 Frontiers in Chemistry SARS-CoV-2 main protease papain-like protease RNA-dependent RNA polymerase neutralizing antibodies host factors |
| title | Druggable targets and therapeutic development for COVID-19 |
| title_full | Druggable targets and therapeutic development for COVID-19 |
| title_fullStr | Druggable targets and therapeutic development for COVID-19 |
| title_full_unstemmed | Druggable targets and therapeutic development for COVID-19 |
| title_short | Druggable targets and therapeutic development for COVID-19 |
| title_sort | druggable targets and therapeutic development for covid 19 |
| topic | SARS-CoV-2 main protease papain-like protease RNA-dependent RNA polymerase neutralizing antibodies host factors |
| url | https://www.frontiersin.org/articles/10.3389/fchem.2022.963701/full |
| work_keys_str_mv | AT xiaohuaduan druggabletargetsandtherapeuticdevelopmentforcovid19 AT laurettaalacko druggabletargetsandtherapeuticdevelopmentforcovid19 AT shuibingchen druggabletargetsandtherapeuticdevelopmentforcovid19 |